Next Chapter In The Acorda Story Will Be A Page Turner
- FDA approval of Plumiaz (3Q14 or earlier) is a key 2014 event that stands to boost revenues by 30%+.
- Advancing clinical development of Ampyra (dalfampridine) in post-stroke deficits may support multi-factored growth of leading asset’s revenue capabilities.
- The early-stage rHIgM22, a remyelinating asset for the treatment of MS, could be a breakthrough, and initial proof of concept is due in early 2015.
- Although shares remain in-line with levels when initially recommending Acorda, we still view the company as an attractive investment that continues to build out its revenue base through product diversification.